Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Shares of cell therapy pioneer Iovance Biotherapeutics ( IOVA ) have risen by 150% since my March 2019 recommendation suggested that readers accumulate dips ahead of key data catalysts. Given that performance is negative year to date shares have recently lost their premium valuation due ...
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) jumped over 51% last month, according to data provided by S&P Global Market Intelligence . While investors were dealing with the broader market sell-off over coronavirus fears, Bloomberg reported that the development-stage biopharma was...
Today, we will see why Iovance Biotherapeutics ( IOVA ) is one of the most attractive clinical-stage oncology picks in March 2020. Company summary Iovance Biotherapeutics is a clinical-stage cell therapy company focused on addressing the huge unmet demand in solid tumor space. The compan...
Image source: The Motley Fool. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Q4 2019 Earnings Call Feb 25, 2020 , 4:30 p.m. ET Operator Continue reading
Iovance Biotherapeutics, Inc. (IOVA) Q4 2019 Results Conference Call February 25, 2020 04:30 PM ET Company Participants Sara Pellegrino - VP, Investor and Public Relations Maria Fardis - President and CEO Friedrich Finckenstein - Chief Medical Officer Tim Morris - CFO Confer...
Iovance Biotherapeutics (NASDAQ: IOVA ): Q4 GAAP EPS of -$0.50 misses by $0.08 . Cash, cash equivalents, short-term investments, and restricted cash of $312.5M Press Release More news on: Iovance Biotherapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
SAN CARLOS, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today reported fourth quarte...
Iovance Biotherapeutics ( IOVA +9.2% ) was halted on a circuit breaker alongside a Bloomberg headline that the company is exploring a potential sale. More news on: Iovance Biotherapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Shares of Agenus (NASDAQ: AGEN) fell as much as 14.1% today after an update from the pipeline underwhelmed investors. The development-stage biopharmaceutical company announced positive interim data from a combination therapy of balstilimab (AGEN2034) and zalifrelimab (AGEN1884) as a second-l...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
8.86%Change Percent:
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-29 18:24:26 ET No investor likes it when one of their stocks is hit with a recommendation downgrade from an analyst. That was the dynamic behind Iovance Biotherapeutics ' (NASDAQ: IOVA) more than 2% decline in value on Monday. A onetime Iovance bull has considerably cooled o...
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and...
2024-07-29 05:15:07 ET Piper Sandler analyst issues NEUTRAL recommendation for IOVA on July 29, 2024 02:11AM ET. The previous analyst recommendation was Overweight. IOVA was trading at $9.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...